Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRKR Marker Therapeutics, Inc.

Closed Good Friday 04-17 16:00:00 EDT

1.15

+0.07

+6.48%

盘后1.15

+0.000.00%

19:53 EDT

High1.18	Low1.06	Vol34.58K
Open1.07	D1 Closing1.08	Amplitude11.11%
Mkt Cap12.32M	Tradable Cap7.50M	Total Shares10.71M
T/O38.17K	T/O Rate0.53%	Tradable Shares6.53M
P/B0.66	ROE-65.81%	EPS-1.19
52wk High5.99	52wk Low0.9500	P/E-0.96
Dividend0.00	Div.Yield0.00	ROA-35.50%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MRKR","market":"US","secType":"STK","nameCN":"Marker Therapeutics, Inc.","latestPrice":1.15,"timestamp":1744920000000,"preClose":1.08,"halted":0,"volume":34577,"hourTrading":{"tag":"盘后","latestPrice":1.15,"preClose":1.15,"latestTime":"19:53 EDT","volume":15,"amount":17.6,"timestamp":1744934003016},"delay":0,"floatShares":6525034,"shares":10709005,"eps":-1.194996,"marketStatus":"Closed Good Friday","change":0.07,"latestTime":"04-17 16:00:00 EDT","open":1.07,"high":1.18,"low":1.06,"amount":38170.9887032,"amplitude":0.111111,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.194996,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.08,"postHourTrading":{"tag":"盘后","latestPrice":1.15,"preClose":1.15,"latestTime":"19:53 EDT","volume":15,"amount":17.6,"timestamp":1744934003016},"volumeRatio":0.997116408495108,"impliedVol":5.7071,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/MRKR","defaultTab":"news","newsList":[{"id":"2524190000","title":"Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524190000","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524190000?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"HOUSTON, April 01, 2025  -- MARKER THERAPEUTICS, INC., a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors,today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity’s Horizons in Oncology Virtual Conference.Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors.CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?Marker Therapeutics is advancing a unique multi antigen recognizing -T cell therapy platform designed to target multiple tumor-associated antigens simultaneously, an approach that has shown promising clinical results in hematologic malignancies and solid tumors.To join the virtual panel discussion, please contact your Cana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/marker-therapeutics-present-canaccord-genuity-120000515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4588","MAR","IE00B1G9WX41.USD","IE00B45NX917.SGD","IE00BD0PCF45.HKD","LU1718418525.SGD","BK4585","IE00B0T0GQ85.USD","IE00B95QR487.USD","LENZ","MRKR","BK4142"],"gpt_icon":0},{"id":"2524949621","title":"Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2524949621","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524949621?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:55","pubTimestamp":1743504927,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst John Newman maintained a Buy rating on Marker Therapeutics (MRKR – Research Report) today and set a price target of $8.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/marker-therapeutics-mrkr-receives-a-buy-from-canaccord-genuity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/marker-therapeutics-mrkr-receives-a-buy-from-canaccord-genuity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2524966541","title":"Marker Therapeutics Price Target Maintained With a $12.50/Share by WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2524966541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524966541?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 18:19","pubTimestamp":1743502740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRKR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 06:19 ET (10:19 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","MRKR"],"gpt_icon":0},{"id":"2523494948","title":"Marker Therapeutics FY Net Income USD -10.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523494948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523494948?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:45","pubTimestamp":1743425100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nPLX459F3A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MRKR"],"gpt_icon":0},{"id":"2523949260","title":"Press Release: Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949260","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949260?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:45","pubTimestamp":1743425100,"startTime":"0","endTime":"0","summary":"Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses. Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas  and the National Institute of Health  Small Business Innovation Research  to support pancreatic and lymphoma clinical programs. Approval from United States Adopted Name  council and International Nonproprietary Names  expert committee for \"neldaleucel\" as nonproprietary name for MT-601. Strategic financing to support clinical advancements to investigate MT-601 in patients with lymphoma. \"In 2024, we made substantial progress advancing MT-601, our lead multi antigen recognizing -T cell therapy, and laid the groundwork for continued momentum in 2025,\" said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. \"Preliminary data ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","INN","LU1718418525.SGD","NEA","MAR","IE00B45NX917.SGD","IE00B1G9WX41.USD","BK4139","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU2065731478.USD","BK4181","IE00B0T0GQ85.USD","LENZ","BK4006","BK4585","BK4142","IE00BD0PCF45.HKD","MRKR","CRS","IE0031619046.USD","BK4588","IE00B95QR487.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2521840047","title":"Marker Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2521840047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521840047?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:49","pubTimestamp":1742557748,"startTime":"0","endTime":"0","summary":"Marker Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to report resultson March 24 (estimated) for the period ending ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR"],"gpt_icon":0},{"id":"2517941882","title":"Marker Therapeutics up 8% After Canaccord Genuity Initiates Coverage With \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517941882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517941882?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 00:19","pubTimestamp":1741191589,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL3N3PO1IE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2517915414","title":"Canaccord Genuity Initiates Marker Therapeutics at Buy With $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2517915414","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517915414?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 20:22","pubTimestamp":1741177326,"startTime":"0","endTime":"0","summary":"Canaccord Genuity Initiates Marker Therapeutics at Buy With $8 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MRKR","LENZ"],"gpt_icon":0},{"id":"2517199424","title":"Marker Therapeutics initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2517199424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517199424?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 18:17","pubTimestamp":1741169821,"startTime":"0","endTime":"0","summary":"Canaccord initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $8 price target Published first on TheFly – the ultimate source fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-initiated-with-a-buy-at-canaccord?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-initiated-with-a-buy-at-canaccord?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRKR","BK4139","LENZ"],"gpt_icon":0},{"id":"2510112798","title":"Marker Therapeutics initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2510112798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510112798?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 07:05","pubTimestamp":1739228705,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-initiated-with-a-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-initiated-with-a-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MRKR","BRKL","BK4211","LENZ"],"gpt_icon":0},{"id":"2502843157","title":"BRIEF-Marker Therapeutics Inc Files For Resale Of Up To 10.1 Million Shares By The Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2502843157","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502843157?lang=en_us&edition=full_marsco","pubTime":"2025-01-11 06:20","pubTimestamp":1736547620,"startTime":"0","endTime":"0","summary":"BRIEF-Marker Therapeutics Inc Files For Resale Of Up To 10.1 Million Shares By The Selling Stockholders - SEC FilingJan 10  - Marker Therapeutics Inc MRKR.O:MARKER THERAPEUTICS INC FILES FOR RESALE OF UP TO 10.1 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILINGSource text: [ID:n0001104659-25-002600]Further company coverage: MRKR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O61CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2502843886","title":"Marker Therapeutics Inc Files for Resale of up to 10.1 Mln Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2502843886","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502843886?lang=en_us&edition=full_marsco","pubTime":"2025-01-11 06:10","pubTimestamp":1736547014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O61CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2492104533","title":"Marker Therapeutics to Raise $16.1 Million in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492104533","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492104533?lang=en_us&edition=full_marsco","pubTime":"2024-12-20 01:38","pubTimestamp":1734629905,"startTime":"0","endTime":"0","summary":"Marker Therapeutics  said Thursday it has agreed to sell securities worth $16.1 million to investors including Blue Owl Healthcare Opportunities , New Enterprise Associates and Aisling Capital in a private placement.Marker said it will sell about 5 million shares, or pre-funded warrants, and warrants to buy up to around 5 million shares at a price of $3.20 per share and accompanying warrant.Net proceeds will be allocated toward supporting the phase 1 Apollo trial studying the company's multi-antigen recognizing T cell product, it added.The company's shares were down 4.2% in recent trading.Price: 3.81, Change: -0.22, Percent Change: -5.46","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MRKR","IE00BBT3K403.USD","IE00BLSP4452.SGD","OWL","BK4135","IE00BN8TJ469.HKD","IE00BLSP4239.USD","LENZ"],"gpt_icon":0},{"id":"2492717633","title":"BRIEF-Marker Therapeutics Provides A Clinical Update On MT-601 In Patients With Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2492717633","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492717633?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 22:13","pubTimestamp":1734617586,"startTime":"0","endTime":"0","summary":"BRIEF-Marker Therapeutics Provides A Clinical Update On MT-601 In Patients With LymphomaDec 19 (Reuters) - Marker Therapeutics Inc MRKR.O:MARKER THERAPEUTICS PROVIDES A CLINICAL UPDATE ON MT-601 IN PA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA2CR3K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2492788941","title":"BUZZ-Marker Therapeutics slides after $16 mln private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492788941","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492788941?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:29","pubTimestamp":1734614987,"startTime":"0","endTime":"0","summary":"BUZZ-Marker Therapeutics slides after $16 mln private placement** Shares of drug developer Marker Therapeutics MRKR.O fall 25.5% to $3 premarket** MRKR announces $16.1 mln private placement** Proceeds from this financing will support the clinical development of MT-601, a next-generation T cell-based therapy for relapsed lymphoma patients - MRKR** Investors to pay a purchase price of $3.20/shr and warrants are exercisable for $4.03/shr** As of last close, stock has fallen 26.7% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK15T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2492178612","title":"Marker Therapeutics sells 5.03M shares at $3.20 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492178612","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492178612?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:25","pubTimestamp":1734614736,"startTime":"0","endTime":"0","summary":"Marker Therapeutics (MRKR) entered into a securities purchase agreement for a private placement resulting in gross proceeds of $16.1M, before deduc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-sells-5-03m-shares-at-3-20-in-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-sells-5-03m-shares-at-3-20-in-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","MRKR","BK4139"],"gpt_icon":0},{"id":"2492510120","title":"Marker Therapeutics provides update on MT-601 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2492510120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492510120?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:10","pubTimestamp":1734613851,"startTime":"0","endTime":"0","summary":"Marker Therapeutics (MRKR) provided an update on the progress and clinical observations from the Phase 1 APOLLO study, with a data cutoff date of S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-provides-update-on-mt-601-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/marker-therapeutics-provides-update-on-mt-601-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MT","BK4006","BK4561","LENZ","MRKR","BK4139"],"gpt_icon":0},{"id":"2492274731","title":"Marker Therapeutics Announces $16.1 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492274731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492274731?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:06","pubTimestamp":1734613603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA5LCDS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRKR","BK4139"],"gpt_icon":0},{"id":"2492127224","title":"Marker Therapeutics Announces $16.1 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127224","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127224?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:06","pubTimestamp":1734613560,"startTime":"0","endTime":"0","summary":"Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells. HOUSTON, Dec. 19, 2024  -- Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has entered into a securities purchase agreement for a private placement resulting in gross proceeds of $16.1 million, before deducting placement agent fees and other expenses.Proceeds from the financing will, among other uses, support the clinical advancement of the Company’s Phase 1 APOLLO study investigating MT-601, a multi-antigen recognizing  T cell product , in patients with lymphoma who have relapsed after anti-CD19 chimeric antigen receptor -T cell therapy or where anti-CD19 CAR-T cells are not an option.The financing included participation from new and existing ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8AJMJw1xrPuopdoh_q90Ig--~B/aD05Nzt3PTM1OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/cf56258bea17002c25114a21eeac65b4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8AJMJw1xrPuopdoh_q90Ig--~B/aD05Nzt3PTM1OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/cf56258bea17002c25114a21eeac65b4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/marker-therapeutics-announces-16-1-130600753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4230","NEA","LENZ","MAR","BK4139","CAR","BK4585","MRKR","BK4588","BK4142","LU1718418525.SGD"],"gpt_icon":0},{"id":"2492493127","title":"Marker Therapeutics Provides a Clinical Update on Mt-601 in Patients With Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2492493127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492493127?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:05","pubTimestamp":1734613550,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA2CR3K0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRKR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.markertherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1165},{"period":"1month","weight":-0.0945},{"period":"3month","weight":-0.5325},{"period":"6month","weight":-0.6733},{"period":"1year","weight":-0.7332},{"period":"ytd","weight":-0.6302}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.069516},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.076427},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.080323},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.006126},{"month":5,"riseRate":0.5,"avgChangeRate":0.232573},{"month":6,"riseRate":0.625,"avgChangeRate":0.292775},{"month":7,"riseRate":0.125,"avgChangeRate":-0.07757},{"month":8,"riseRate":0.375,"avgChangeRate":0.002117},{"month":9,"riseRate":0.25,"avgChangeRate":-0.071254},{"month":10,"riseRate":0.375,"avgChangeRate":-0.038018},{"month":11,"riseRate":0.25,"avgChangeRate":-0.08549},{"month":12,"riseRate":0.222222,"avgChangeRate":0.037661}],"exchange":"NASDAQ","name":"Marker Therapeutics, Inc.","nameEN":"Marker Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Marker Therapeutics, Inc.(MRKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Marker Therapeutics, Inc.,MRKR,Marker Therapeutics, Inc.股票,Marker Therapeutics, Inc.股票老虎,Marker Therapeutics, Inc.股票老虎国际,Marker Therapeutics, Inc.行情,Marker Therapeutics, Inc.股票行情,Marker Therapeutics, Inc.股价,Marker Therapeutics, Inc.股市,Marker Therapeutics, Inc.股票价格,Marker Therapeutics, Inc.股票交易,Marker Therapeutics, Inc.股票购买,Marker Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Marker Therapeutics, Inc.(MRKR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Marker Therapeutics, Inc.(MRKR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction